Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development.
about
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae.Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome"Prophylactic versus selective antibiotics for term newborn infants of mothers with risk factors for neonatal infectionMaternal and neonatal colonisation of group B streptococcus at Muhimbili National Hospital in Dar es Salaam, Tanzania: prevalence, risk factors and antimicrobial resistanceTranscriptome adaptation of group B Streptococcus to growth in human amniotic fluid.Genotyping of Streptococcus agalactiae (group B streptococci) isolated from vaginal and rectal swabs of women at 35-37 weeks of pregnancy.Relationship between antenatal group B streptococcal vaginal colonization and premature labour.Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis.Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.Regulation of virulence by a two-component system in group B streptococcus.Physicians' prevention practices and incidence of neonatal group B streptococcal disease in 2 Canadian regions.Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates.Epidemiology of group B streptococcal disease in the United States: shifting paradigms.Regulation of cell component production by growth rate in the group B Streptococcus.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Understanding the bacterial flora of the female genital tract.History of antibiotics. From salvarsan to cephalosporins.The prevalence of Group B Streptococus recto-vaginal colonization and antimicrobial susceptibility pattern in pregnant mothers at two hospitals of Addis Ababa, Ethiopia.Ampicillin susceptibilities of vaginal and placental isolates of group B streptococcus and Escherichia coli obtained between 1992 and 1994.Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons.Cell growth rate regulates expression of group B Streptococcus type III capsular polysaccharide.Compliance with a protocol for intrapartum antibiotic prophylaxis against neonatal group B streptococcal sepsis in women with clinical risk factors.Characterization of a small mobilizable transposon, MTnSag1, in Streptococcus agalactiaeStreptococcus agalactiae Septic Arthritis of the Shoulder and the Sacroiliac Joints: A Case ReportAppropriateness of Intrapartum Antibiotic Prophylaxis to Prevent Neonatal Group B Streptococcus DiseaseHuman Milk Oligosaccharides Exhibit Antimicrobial and Antibiofilm Properties against Group B Streptococcus.Chorioamnionitis and Culture-Confirmed, Early-Onset Neonatal Infections.Adherence to, invasion by, and cytokine production in response to serotype VIII group B Streptococci.Variation in the group B Streptococcus CsrRS regulon and effects on pathogenicity.Decreased capacity for type-specific-antigen synthesis accounts for high prevalence of nontypeable strains of group B streptococci in Mexico.Statistical models for vaginal microflora: identifying women at risk for group B streptococcus colonization as a test of concept.Maternal colonization with Streptococcus agalactiae and associated stillbirth and neonatal disease in coastal Kenya.Epidemiology of neonatal group B streptococcal disease in the Netherlands before and after introduction of guidelines for prevention.The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women.Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.Contribution of the RgfD Quorum Sensing Peptide to rgf Regulation and Host Cell Association in Group B Streptococcus.Metabolic and toxicological considerations for sepsis drug treatments.Group B streptococcal immunisation of pregnant women for the prevention of early and late onset Group B streptococcal infection of the neonate as well as adult disease.Colonization prevalence and antibiotic susceptibility of Group B Streptococcus in pregnant women over a 6-year period in Dongguan, China.
P2860
Q22066228-B04DD584-5A60-461C-A2A7-07330EB14B2BQ22066389-4B542668-C259-4676-A6EE-F80CE81AFAE0Q24245689-8B96E197-68BC-47D2-9268-37EE60219449Q30932464-BC9FB0A6-3913-41BD-AAFB-D29C7615650CQ33476853-2D77ABC0-03BD-4493-9476-F3F57265526EQ33502355-D75B819A-43C5-4C70-812D-6B188D6F36BBQ33684839-DAFB7946-E86D-493C-8C74-00014F0EE560Q33693750-6A5D02F7-79E7-49F5-AD20-AE63B27AFAF5Q33715970-EB108A97-4BA0-4711-82E4-72FF4AFE6A3CQ33758224-A3CF0D64-F75B-40F8-ACDC-89594BFB99EAQ33955268-8489182F-491F-4564-8F64-42A4EA86AD27Q33961984-34EB5A10-515C-4800-8499-592C94262D2FQ33975346-F0BFA3A4-A69A-4E7F-8209-EE00CBE926F5Q33992857-F44B406C-8F57-4352-A897-5455881E0B28Q34112608-D189A2E4-5326-45C5-B96A-D67819AAF128Q34142051-22E05BFB-598E-4B53-BD75-DF2A84E3B451Q34262986-83CAC6B4-1445-45F8-ADAD-B4AE73AF8687Q34695905-FCA44F0B-0C9A-427E-A5BF-6A7B343ECFF2Q35136323-3666C90E-0584-4FDC-B25A-AE6607E6C428Q35470773-6E9A976D-D722-4901-8164-2E9A6267CECBQ35481196-32520F6F-06DD-485B-8681-CEB6B2A00EA7Q35614740-EC48207E-F989-4E1B-AA2D-73D1DF990B54Q35879324-77D3777F-6539-4DFE-823C-C067C967E9F0Q36180516-0C4E0FD7-507C-48FC-9A60-5EF356FEB376Q36197392-70AB3871-02C7-4B6D-8F7E-04EA57AEE5B9Q36389680-EA4B09F0-1751-40F7-A63C-C0A68957738BQ36432173-C0AE10FF-FAE6-41B5-99AE-29793CD212E3Q36447095-44E2C009-F05B-4B76-9E35-5976D48776CCQ36483768-AFFEDAFA-A4B7-42C8-97C7-87A8E2B65048Q36547591-E6AF5818-01C9-494D-AAA7-18F1A9732D7CQ36625468-D16C35A8-3983-449A-A9B6-85D629486D50Q37074413-339CAE63-04E6-4D13-9B2F-89F2BCAA9338Q37174864-A172EFD8-B018-483F-987A-DB89E165B402Q37175822-0605B67D-142D-4B09-BBE0-70D16E78C310Q37258108-97526A2C-45EE-4A32-A0DB-B23F15DA4C84Q37361495-78160A53-FAF6-4116-A3B6-20BDF68C40AAQ37628267-C258D0A4-0E39-4A03-B3E5-8B83658F4AA2Q38045406-756F0658-A71B-4C96-826A-C216F76C62A5Q38844623-E6D1D435-2B83-4CE4-8AD9-DA63C5B83E3AQ40091480-707E4F37-62ED-4E99-8703-0F977607F5A9
P2860
Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Epidemiology of group B strept ...... gies, and vaccine development.
@en
type
label
Epidemiology of group B strept ...... gies, and vaccine development.
@en
prefLabel
Epidemiology of group B strept ...... gies, and vaccine development.
@en
P1476
Epidemiology of group B strept ...... gies, and vaccine development.
@en
P2093
P304
P356
10.1093/OXFORDJOURNALS.EPIREV.A036159
P577
1994-01-01T00:00:00Z